NASDAQ · VRDN
Viridian Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for VRDN: Nov 04, 2026
Viridian Therapeutics, Inc. Common Stock is expected to report earnings on 11/04/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.08. The reported EPS for the same quarter last year was $-0.34.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.08 | $-0.93 | $-1.34 | 5 |
| Dec 2026 | $-0.94 | $-0.82 | $-1.21 | 5 |
| Mar 2027 | $-0.73 | $-0.68 | $-0.78 | 2 |
| Jun 2027 | $-0.59 | $-0.49 | $-0.68 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · Barchart · The Motley Fool- RTTNews · Jul 2, 10:09 AM EDTWeekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal(RTTNews) – The holiday-shortened week delivered no shortage of action for the biotech sector, with a mix of FDA, China, Canada, and EU approvals, acquisitions, and positive clinical readouts, alongside regulatory rejections, program discontinuations, and trial goal misses.
- Zacks · Jul 1, 10:41 AM EDTVRDN Stock Rises 6.3% in a Week: Here's What You Need to KnowViridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expanded labeling and plans for an immediate U.S. launch.
- Barchart · Jun 30, 1:59 PM EDTStock Indexes Finish Sharply Higher as Tech SoarsThe S&P 500 Index ($SPX ) (SPY ) on Monday closed up +1.18%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.59%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +2.25%. September E-mini S&P futures (ESU26 ) rose +1.20%, and September E-mini Nasdaq futures…
- Barchart · Jun 29, 6:46 PM EDTStock Indexes Push Higher as Megacap Tech Stocks RallyThe S&P 500 Index ($SPX ) (SPY ) is up +0.73% today; the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.64%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.08%. September E-mini S&P futures (ESU26 ) are up +0.76%, and September E-mini Nasdaq futures…
- Barchart · Jun 29, 5:23 PM EDTStock Indexes Supported by Strength in Megacap Tech StocksThe S&P 500 Index ($SPX ) (SPY ) today is up +0.59%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.64%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.67%. September E-mini S&P futures (ESU26 ) are up +0.73%, and September E-mini Nasdaq futures…
- RTTNews · Jun 26, 11:23 PM EDTViridian Wins FDA Approval For Lumvoa In Thyroid Eye Disease; Stock Up(RTTNews) – Viridian Therapeutics, Inc. (VRDN) announced that the U.S. FDA has approved Lumvoa for the treatment of thyroid eye disease, marking the company's first commercial product and a major milestone in its transition to a commercial-stage biopharma.
- RTTNews · Jun 3, 10:01 AM EDTBiotech Stocks Facing FDA Decision In June 2026(RTTNews) – The month of May saw important regulatory developments, with the FDA approving new therapies for rare and underserved patient populations.
- The Motley Fool · May 17, 2:52 PM EDTThis Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 MillionHighVista Strategies sold 238,243 shares of Viridian Therapeutics; the estimated trade size was $7.08 million based on average closing prices from January through March 2026.
- RTTNews · May 8, 8:17 AM EDTWeekly Buzz:FDA Clears Tab-cel Path, Arvinas Wins PROTAC Nod, Novartis Cuts Jobs, Roche Buys PathAI(RTTNews) – This week's biotech roundup features the FDA's path forward for Atara's tab-cel, Arvinas' first-in-class PROTAC approval, and Incyte's Jakafi XR securing a regulatory nod. The week also saw Novartis announcing a site closure, Roche striking a $750 million PathAI deal,
- RTTNews · May 5, 11:06 AM EDTViridian Therapeutics Q1 Net Loss Widens; Veligrotug's Decision Due In June; Stock Up(RTTNews) – Viridian Therapeutics, Inc. (VRDN), a biotechnology company, reported financial results for the first quarter ended March 31, 2026, reflecting a wider net loss. In addition, the firm highlighted recent business developments and a near-term milestone for its developme
- The Motley Fool · Apr 21, 3:46 PM EDTKopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake — What Investors Should KnowKopp sold 117,878 shares of Viridian Therapeutics; the estimated transaction value was $3.5 million based on quarterly average pricing.
- Zacks · Apr 7, 9:51 AM EDTAMGN's Subcutaneous Tepezza Scores Phase III Win in Thyroid Eye DiseaseAmgen's subcutaneous Tepezza hits phase III goals in thyroid eye disease, matches IV efficacy and offers faster dosing that could expand access.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Viridian Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.